Can Endocannabinoids Explain CBD-Mediated Reduction in Blood Pressure? Insights from a Randomized,...

Area of Science:

• Cardiovascular Pharmacology
• Endocannabinoid System Research
• Hypertension Therapeutics

Background:

• The HYPER-H21-4 trial demonstrated that chronic cannabidiol (CBD) reduces blood pressure (BP) in hypertensive patients.
• The endocannabinoid (EC) system is implicated in hypertension, prompting investigation into its role in CBD's cardiovascular effects.

Purpose of the Study:

• To investigate if changes in circulating endocannabinoids (ECs) mediate the blood pressure-lowering effects of CBD.
• To determine the impact of chronic CBD administration on plasma levels of anandamide (AEA) and 2-arachidonoylglycerol (2-AG).

Main Methods:

• A randomized, placebo-controlled, crossover trial involving 66 patients with primary hypertension.
• Patients received either CBD (225-450 mg/day) or placebo for 5 weeks, followed by a crossover period.
• Plasma AEA and 2-AG levels were measured throughout the study, alongside BP monitoring.

Main Results:

• Chronic CBD administration significantly increased plasma AEA levels compared to placebo.
• No significant association was found between changes in AEA levels and changes in systolic blood pressure.
• Chronic CBD administration did not significantly alter plasma 2-AG concentrations.

Conclusions:

• CBD supplementation increases circulating AEA levels in hypertensive patients.
• The observed increase in AEA levels does not conclusively explain the blood pressure-reducing effects of CBD.
• Further research is needed to elucidate the precise mechanisms underlying CBD's antihypertensive actions.